20/20 BioLabs Q3 revenue slips to $0.38M; Vermont firefighter cancer screening contract signed
The US diagnostics company reported a third-quarter net loss of $1.38M, while a two-year Vermont screening deal is expected to add revenue in the fourth quarter.
16 Nov 2026 · 20/20 Biolabs, Inc. AIDX · Company news
20/20 BioLabs reported results for the quarter ended 30 September 2026 in a release dated 16 November. Third-quarter revenue was $0.38M, down from $0.42M in the same period a year earlier, and the company recorded a net loss of $1.38M.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): 20/20 Biolabs, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027
16 Nov 2026 · Lifeloc Technologies, Inc LCTC · Company news
Earnings
Glass House Brands more than doubles Q3 revenue to $56.8M as net loss narrows
16 Nov 2026 · Glass House Brands Inc. GLAS · Company news
Earnings
Acrivon adds oral JAK1 inhibitor ACR-525 as ACR-368 interim analysis nears
16 Nov 2026 · Acrivon Therapeutics, Inc. ACRV · Company news
Earnings
Omeros Q3 sales of Yartemlea rise 26% as CHMP upholds negative opinion on narsoplimab
16 Nov 2026 · Omeros Corp OMER · Company news
Earnings
Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M
16 Nov 2026 · Rapid Micro Biosystems, Inc. RPID · Company news
Earnings
Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative
16 Nov 2026 · Microbot Medical Inc. MBOT · Company news